NEW YORK (GenomeWeb News) — Fluidigm reported after the market closed on Wednesday that its third quarter revenues increased 43 percent year over year, driven by growth in both consumables and instrumentation, and particularly by single-cell genomics applications.

The firm's shares spiked in Thursday morning trade on the Nasdaq, rising 18 percent to $30.00.

For the three months ended September 30, total revenues were $18.3 million compared to $12.8 million for the third quarter of 2012, and beating the average Wall Street estimate of $16.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.